Topic is suspended
Status Suspended
Decision Selected
Process TA
ID number 1668

Email enquiries


Key events during the development of the guidance:

Date Update
21 April 2021 Expected publication
12 November 2020 Suspended. Topic is suspended
12 November 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
16 April 2020 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
16 December 2019 In progress. Referred October 17 2018

For further information on our processes and methods, please see our CHTE processes and methods manual